StockMacro
Company, fund or insider

Help

Menu

DexCom

$79.32 +10% in 6 monthsMarket cap $29.6B

DXCM on XNAS, Health Care, DexCom, Inc., job postings

Measures activity, not value. Not investment advice.

Profit rose 38% to $991M on 13% revenue growth as shares gained 36% in a year.

  • WatchCapital spending fell 34% to $52.9M in the latest quarter

Written by AI from the data on this page, 21 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.

Industry
Surgical & medical instruments & apparatus (Health Care)
Employees
11,100
Website
dexcom.com
Listed
Nasdaq, US
Last results
29 Oct 2026
Next results
expected around 11 Jan 2027 (an estimate: a year ago it reported on 12 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $1.3B, net income $275.1M.
Quarter to 31 Dec 2021: revenue $698.2M, net income -$19.4MQuarter to 31 Dec 2021: revenue $698.2M, net income -$19.4MQuarter to 31 Mar 2022: revenue $628.8M, net income $97.3MQuarter to 31 Mar 2022: revenue $628.8M, net income $97.3MQuarter to 30 Jun 2022: revenue $696.2M, net income $50.9MQuarter to 30 Jun 2022: revenue $696.2M, net income $50.9MQuarter to 30 Sep 2022: revenue $769.6M, net income $101.2MQuarter to 30 Sep 2022: revenue $769.6M, net income $101.2MQuarter to 31 Dec 2022: revenue $815.2M, net income –Quarter to 31 Mar 2023: revenue $741.5M, net income $48.6MQuarter to 31 Mar 2023: revenue $741.5M, net income $48.6MQuarter to 30 Jun 2023: revenue $871.3M, net income $115.9MQuarter to 30 Jun 2023: revenue $871.3M, net income $115.9MQuarter to 30 Sep 2023: revenue $975.0M, net income $120.7MQuarter to 30 Sep 2023: revenue $975.0M, net income $120.7MQuarter to 31 Dec 2023: revenue $1.0B, net income –Quarter to 31 Mar 2024: revenue $921.0M, net income $146.4MQuarter to 31 Mar 2024: revenue $921.0M, net income $146.4MQuarter to 30 Jun 2024: revenue $1.0B, net income $143.5MQuarter to 30 Jun 2024: revenue $1.0B, net income $143.5MQuarter to 30 Sep 2024: revenue $994.2M, net income $134.6MQuarter to 30 Sep 2024: revenue $994.2M, net income $134.6MQuarter to 31 Dec 2024: revenue $1.1B, net income $151.7MQuarter to 31 Dec 2024: revenue $1.1B, net income $151.7MQuarter to 31 Mar 2025: revenue $1.0B, net income $105.4MQuarter to 31 Mar 2025: revenue $1.0B, net income $105.4MQuarter to 30 Jun 2025: revenue $1.2B, net income $179.8MQuarter to 30 Jun 2025: revenue $1.2B, net income $179.8MQuarter to 30 Sep 2025: revenue $1.2B, net income $283.8MQuarter to 30 Sep 2025: revenue $1.2B, net income $283.8MQuarter to 31 Dec 2025: revenue $1.3B, net income $267.3MQuarter to 31 Dec 2025: revenue $1.3B, net income $267.3MQuarter to 31 Mar 2026: revenue $1.2B, net income $199.5MQuarter to 31 Mar 2026: revenue $1.2B, net income $199.5MQuarter to 30 Jun 2026: revenue $1.3B, net income $249.1MQuarter to 30 Jun 2026: revenue $1.3B, net income $249.1MQuarter to 30 Sep 2026: revenue $1.3B, net income $275.1MQuarter to 30 Sep 2026: revenue $1.3B, net income $275.1M
31 Dec 2021RevenueNet incomeNet losstallest bar $1.3B30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$1.3B$275.1M
30 Jun 2026$1.3B$249.1M
31 Mar 2026$1.2B$199.5M
31 Dec 2025$1.3B$267.3M
30 Sep 2025$1.2B$283.8M
30 Jun 2025$1.2B$179.8M
31 Mar 2025$1.0B$105.4M
31 Dec 2024$1.1B$151.7M
30 Sep 2024$994.2M$134.6M
30 Jun 2024$1.0B$143.5M
31 Mar 2024$921.0M$146.4M
31 Dec 2023$1.0B–
30 Sep 2023$975.0M$120.7M
30 Jun 2023$871.3M$115.9M
31 Mar 2023$741.5M$48.6M
31 Dec 2022$815.2M–
30 Sep 2022$769.6M$101.2M
30 Jun 2022$696.2M$50.9M
31 Mar 2022$628.8M$97.3M
31 Dec 2021$698.2M-$19.4M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $5.1B $4.5B
Revenue growthRevenue of the last 12 months compared with the 12 months before. +13% +13%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. $991.0M $720.7M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). $2.54 $1.80
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 63.4% 59.0% 60.5%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. 24.0% 17.2% -8.3%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. 19.4% 16.0% -10.1%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. 37.7% -26.3%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. $1.1B $1.1B
CashCash, cash equivalents and short-term investments on the latest balance sheet. $1.7B $3.2B
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $1.2B $2.4B
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$440.6M (net cash) -$798.9M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.49 0.31
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $6.80
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. 29.9 28.0
P/SPrice to sales: market cap divided by revenue of the last 12 months. 5.8 2.3
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 5.7 2.5
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 11.7 2.8

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
DexComDXCM (this company) $29.6B29.95.8+13%19.4%
West Pharmaceutical ServicesWST $27.2B42.68.0+13%18.8%
MedlineMDLN $32.5B36.61.1–2.9%
ResMedRMD $33.1B20.85.8+9.0%27.8%
Becton, Dickinson andBDX $58.0B61.62.8+5.2%4.5%
Boston ScientificBSX $60.8B17.42.9+8.9%16.6%

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+11%

$1.3B vs $1.2B (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

-34%

$52.9M vs $80.5M (quarter ended 30 Sep 2026)

Insider buy/sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$4.5M

bought $0, sold $4.5M

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+9.1%

1,038 13F filers vs 951

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

98%

365.8M shares held by 13F filers (30 Sep 2026) of 373.0M outstanding (22 Oct 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

4.3%

15.9M shares sold short (30 Oct 2026) of 373.0M outstanding (22 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

2.8

15.9M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+1.6%

15.7M shares sold short in the report before, 15.9M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

58%

58% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 50%

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

-3.9%

49 vs 51 applications

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$1.5M

4 quarters

News Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

39

39 articles in the last 7 days; its usual week has 7.5 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

5.2×

39 articles in the last 7 days; its usual week has 7.5.

Price $79.32 on 20 Nov 2026, +36% over 12 months (12-month range $57.56 to $92.34)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $12.7M in the last 12 months (the 12 months before: -$13.1M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 48 published in the last 12 months, -7.7% on the 12 months before.
Revenue per quarter. Revenue $1.3B in the latest quarter, +11% on a year earlier.
Capital spending per quarter. Capital spending $52.9M in the latest quarter, -34% on a year earlier.
Institutional holders (13F filers). 1,038 13F filers reported holding it in the latest 13F quarter, +20% on a year earlier.
Lobbying spend. Lobbying spend: $1.5M published in the last 12 months, +23% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
19 Oct 2026Lobbying filinglobbying engagement terminated (CONTINENTAL STRATEGY, LLC)
14 Sep 20268-K and other filingsDirector or officer change
10 Sep 20268-K and other filingsDirector or officer change
10 Sep 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
15 Jun 2026Lobbying filingnew lobbying registration (BGR GOVERNMENT AFFAIRS)
2 Mar 20268-K and other filingsDirector or officer change
26 Feb 20268-K and other filingsDirector or officer change
22 Dec 20258-K and other filingsDirector or officer change
27 Oct 20258-K and other filingsDirector or officer change
15 Sep 20258-K and other filingsDirector or officer change
30 Jul 20258-K and other filingsDirector or officer change
21 Jul 2025Sharp changeLobbying on a new issue: lobbying on a new issue: MED (2025-06-30)
11 Jun 2025Lobbying filingnew lobbying registration (CONTINENTAL STRATEGY, LLC)
13 May 20258-K and other filingsDirector or officer change
9 May 20258-K and other filingsDirector or officer change
2 May 20258-K and other filingsDirector or officer change
25 Mar 20258-K and other filingsChanged its auditor
10 Mar 20258-K and other filingsDirector or officer change
10 Mar 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
25 Feb 2025Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 124.6M vs usual 61.2M (2024-12-31); 2.4x the same period a year earlier
21 Jan 2025Sharp changeLobbying spend jump: lobbying spend jump, 260K vs usual 67K (2024-12-31); 4.6x the same period a year earlier
29 Oct 2024Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 111.2M vs usual 61.2M (2024-09-30); 2.2x the same period a year earlier
27 Sep 2024Lobbying filingnew lobbying registration (FARRAGUT PARTNERS LLP)
10 Sep 2024Sharp changeLobbying spend jump: lobbying spend jump, 170K vs usual 60K (2024-06-30); 2.5x the same period a year earlier
22 Apr 2024Sharp changeLobbying on a new issue: lobbying on a new issue: TRD (2024-03-31)
15 Feb 20248-K and other filingsA major agreement ended
13 Feb 2024Sharp changeQuarterly revenue change: quarterly revenue change, 1.0B vs usual 755.5M (2023-12-31); 1.3x the same period a year earlier
28 Nov 2023Sharp changeShort interest spike: short interest spike, 17.7M vs usual 12.8M (2023-11-15); 1.4x the same period a year earlier
14 Nov 2023Sharp changeShort interest spike: short interest spike, 21.1M vs usual 12.7M (2023-10-31); 1.8x the same period a year earlier
28 Aug 20238-K and other filingsDirector or officer change
28 Aug 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
19 May 20238-K and other filingsDirector or officer change
19 May 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
14 Feb 2023Sharp changeMany funds opening a new position: many funds opening a new position, 123 vs usual 69.50 (2022-12-31); 1.0x the same period a year earlier
13 Dec 2022Sharp changeShort interest spike: short interest spike, 13.0M vs usual 3.7M (2022-11-30); 3.6x the same period a year earlier
29 Nov 2022Sharp changeShort interest spike: short interest spike, 12.6M vs usual 3.6M (2022-11-15); 3.4x the same period a year earlier
15 Nov 2022Sharp changeShort interest spike: short interest spike, 11.9M vs usual 3.6M (2022-10-31); 3.3x the same period a year earlier
1 Nov 2022Sharp changeShort interest spike: short interest spike, 13.7M vs usual 3.6M (2022-10-14); 3.9x the same period a year earlier
20 Oct 2022Sharp changeLobbying on a new issue: lobbying on a new issue: ECN (2022-09-30)
18 Oct 2022Sharp changeShort interest spike: short interest spike, 13.1M vs usual 3.6M (2022-09-30); 3.8x the same period a year earlier
27 Sep 2022Sharp changeShort interest spike: short interest spike, 15.3M vs usual 3.6M (2022-09-15); 4.2x the same period a year earlier
13 Sep 2022Sharp changeShort interest spike: short interest spike, 14.4M vs usual 3.6M (2022-08-31); 3.7x the same period a year earlier
31 Aug 20228-K and other filingsDirector or officer change
30 Aug 2022Sharp changeShort interest spike: short interest spike, 13.4M vs usual 3.6M (2022-08-15); 3.4x the same period a year earlier
16 Aug 2022Sharp changeShort interest spike: short interest spike, 12.2M vs usual 3.6M (2022-07-29); 2.9x the same period a year earlier
2 Aug 2022Sharp changeShort interest spike: short interest spike, 11.7M vs usual 3.6M (2022-07-15); 2.7x the same period a year earlier
19 Jul 2022Sharp changeShort interest spike: short interest spike, 12.1M vs usual 3.6M (2022-06-30); 3.0x the same period a year earlier
8 Jul 20228-K and other filingsDirector or officer change
8 Jul 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
28 Jun 2022Sharp changeShort interest spike: short interest spike, 13.0M vs usual 3.6M (2022-06-15); 3.4x the same period a year earlier
17 Dec 20218-K and other filingsDirector or officer change
17 Dec 2021Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Nov 2021: -$2.9M published
Month from 1 Dec 2021: -$3.0M published
Month from 1 Jan 2022: -$10.0M published
Month from 1 Feb 2022: -$3.4M published
Month from 1 Mar 2022: -$4.4M published
Month from 1 Apr 2022: -$497K published
Month from 1 May 2022: -$340K published
Month from 1 Jun 2022: -$253K published
Month from 1 Jul 2022: -$83K published
Month from 1 Aug 2022: -$84K published
Month from 1 Sep 2022: -$408 published
Month from 1 Nov 2022: -$270K published
Month from 1 Dec 2022: -$1.2M published
Month from 1 Jan 2023: -$4.9M published
Month from 1 Feb 2023: -$6.6M published
Month from 1 Mar 2023: -$8.4M published
Month from 1 Apr 2023: -$8.2M published
Month from 1 May 2023: -$378K published
Month from 1 Jun 2023: -$375K published
Month from 1 Jul 2023: -$1.0M published
Month from 1 Aug 2023: -$280K published
Month from 1 Sep 2023: -$207K published
Month from 1 Oct 2023: -$113K published
Month from 1 Nov 2023: -$723K published
Month from 1 Dec 2023: -$1.6M published
Month from 1 Jan 2024: -$6.0M published
Month from 1 Feb 2024: -$393K published
Month from 1 Mar 2024: -$21.3M published
Month from 1 Apr 2024: -$7.1M published
Month from 1 May 2024: -$386K published
Month from 1 Jun 2024: -$1.2M published
Month from 1 Aug 2024: -$45K published
Month from 1 Sep 2024: -$251K published
Month from 1 Nov 2024: -$583K published
Month from 1 Dec 2024: -$224K published
Month from 1 Jan 2025: -$3.6M published
Month from 1 Mar 2025: -$6.4M published
Month from 1 May 2025: -$1.4M published
Month from 1 Jun 2025: -$788K published
Month from 1 Jul 2025: -$532K published
Month from 1 Aug 2025: -$263K published
Month from 1 Sep 2025: -$529K published
Month from 1 Nov 2025: $554K published
Month from 1 Feb 2026: -$69K published
Month from 1 Mar 2026: -$110K published
Month from 1 Apr 2026: -$107K published
Month from 1 May 2026: -$2.1M published
Month from 1 Jun 2026: -$1.1M published
Month from 1 Jul 2026: -$4.1M published
Month from 1 Aug 2026: -$3.2M published
Month from 1 Sep 2026: -$1.1M published
Month from 1 Oct 2026: -$568K published
Month from 1 Nov 2026: -$142K published
H-1B/E-3 applications certified
Quarter from 1 Jan 2022: 12 published
Quarter from 1 Apr 2022: 10 published
Quarter from 1 Jul 2022: 22 published
Quarter from 1 Oct 2022: 13 published
Quarter from 1 Jan 2023: 7 published
Quarter from 1 Apr 2023: 14 published
Quarter from 1 Jul 2023: 29 published
Quarter from 1 Oct 2023: 10 published
Quarter from 1 Jan 2024: 6 published
Quarter from 1 Apr 2024: 5 published
Quarter from 1 Jul 2024: 19 published
Quarter from 1 Oct 2024: 10 published
Quarter from 1 Jan 2025: 8 published
Quarter from 1 Apr 2025: 7 published
Quarter from 1 Jul 2025: 23 published
Quarter from 1 Oct 2025: 14 published
Quarter from 1 Jan 2026: 4 published
Quarter from 1 Apr 2026: 8 published
Quarter from 1 Jul 2026: 23 published
Quarter from 1 Oct 2026: 13 published
Revenue per quarter
Quarter ended 31 Dec 2021: $698.2M, +23% on a year earlier; public on 15 Feb 2022
Quarter ended 31 Mar 2022: $628.8M, +25% on a year earlier; public on 29 Apr 2022
Quarter ended 30 Jun 2022: $696.2M, +17% on a year earlier; public on 29 Jul 2022
Quarter ended 30 Sep 2022: $769.6M, +18% on a year earlier; public on 28 Oct 2022
Quarter ended 31 Dec 2022: $815.2M, +17% on a year earlier; public on 10 Feb 2023
Quarter ended 31 Mar 2023: $741.5M, +18% on a year earlier; public on 28 Apr 2023
Quarter ended 30 Jun 2023: $871.3M, +25% on a year earlier; public on 28 Jul 2023
Quarter ended 30 Sep 2023: $975.0M, +27% on a year earlier; public on 27 Oct 2023
Quarter ended 31 Dec 2023: $1.0B, +27% on a year earlier; public on 9 Feb 2024
Quarter ended 31 Mar 2024: $921.0M, +24% on a year earlier; public on 26 Apr 2024
Quarter ended 30 Jun 2024: $1.0B, +15% on a year earlier; public on 26 Jul 2024
Quarter ended 30 Sep 2024: $994.2M, +2.0% on a year earlier; public on 25 Oct 2024
Quarter ended 31 Dec 2024: $1.1B, +7.6% on a year earlier; public on 19 Feb 2025
Quarter ended 31 Mar 2025: $1.0B, +12% on a year earlier; public on 2 May 2025
Quarter ended 30 Jun 2025: $1.2B, +15% on a year earlier; public on 31 Jul 2025
Quarter ended 30 Sep 2025: $1.2B, +22% on a year earlier; public on 31 Oct 2025
Quarter ended 31 Dec 2025: $1.3B, +13% on a year earlier; public on 13 Feb 2026
Quarter ended 31 Mar 2026: $1.2B, +15% on a year earlier; public on 1 May 2026
Quarter ended 30 Jun 2026: $1.3B, +13% on a year earlier; public on 31 Jul 2026
Quarter ended 30 Sep 2026: $1.3B, +11% on a year earlier; public on 30 Oct 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $80.2M, +33% on a year earlier; public on 15 Feb 2022
Quarter ended 31 Mar 2022: $101.6M, +1.9% on a year earlier; public on 29 Apr 2022
Quarter ended 30 Jun 2022: $91.5M, -9.6% on a year earlier; public on 29 Jul 2022
Quarter ended 30 Sep 2022: $108.2M, +0.1% on a year earlier; public on 28 Oct 2022
Quarter ended 31 Dec 2022: $63.5M, -21% on a year earlier; public on 10 Feb 2023
Quarter ended 31 Mar 2023: $74.7M, -26% on a year earlier; public on 28 Apr 2023
Quarter ended 30 Jun 2023: $59.0M, -36% on a year earlier; public on 28 Jul 2023
Quarter ended 30 Sep 2023: $50.4M, -53% on a year earlier; public on 27 Oct 2023
Quarter ended 31 Dec 2023: $52.5M, -17% on a year earlier; public on 9 Feb 2024
Quarter ended 31 Mar 2024: $56.9M, -24% on a year earlier; public on 26 Apr 2024
Quarter ended 30 Jun 2024: $66.1M, +12% on a year earlier; public on 26 Jul 2024
Quarter ended 30 Sep 2024: $111.2M, +121% on a year earlier; public on 25 Oct 2024
Quarter ended 31 Dec 2024: $124.6M, +137% on a year earlier; public on 19 Feb 2025
Quarter ended 31 Mar 2025: $87.0M, +53% on a year earlier; public on 2 May 2025
Quarter ended 30 Jun 2025: $94.1M, +42% on a year earlier; public on 31 Jul 2025
Quarter ended 30 Sep 2025: $80.5M, -28% on a year earlier; public on 31 Oct 2025
Quarter ended 31 Dec 2025: $101.9M, -18% on a year earlier; public on 13 Feb 2026
Quarter ended 31 Mar 2026: $76.6M, -12% on a year earlier; public on 1 May 2026
Quarter ended 30 Jun 2026: $84.7M, -10% on a year earlier; public on 31 Jul 2026
Quarter ended 30 Sep 2026: $52.9M, -34% on a year earlier; public on 30 Oct 2026
Institutional holders (13F filers)
31 Dec 2021 report: 820; public on 14 Feb 2022
31 Mar 2022 report: 805; public on 16 May 2022
30 Jun 2022 report: 748; public on 15 Aug 2022
30 Sep 2022 report: 720; public on 14 Nov 2022
31 Dec 2022 report: 828; public on 14 Feb 2023
31 Mar 2023 report: 832; public on 15 May 2023
30 Jun 2023 report: 867; public on 14 Aug 2023
30 Sep 2023 report: 824; public on 14 Nov 2023
31 Dec 2023 report: 891; public on 14 Feb 2024
31 Mar 2024 report: 971; public on 15 May 2024
30 Jun 2024 report: 942; public on 14 Aug 2024
30 Sep 2024 report: 830; public on 14 Nov 2024
31 Dec 2024 report: 896; public on 14 Feb 2025
31 Mar 2025 report: 883; public on 15 May 2025
30 Jun 2025 report: 892; public on 14 Aug 2025
30 Sep 2025 report: 863; public on 14 Nov 2025
31 Dec 2025 report: 881; public on 17 Feb 2026
31 Mar 2026 report: 934; public on 15 May 2026
30 Jun 2026 report: 951; public on 14 Aug 2026
30 Sep 2026 report: 1,038; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Jan 2022: $57K published
Quarter from 1 Apr 2022: $57K published
Quarter from 1 Jul 2022: $57K published
Quarter from 1 Oct 2022: $56K published
Quarter from 1 Jan 2023: $62K published
Quarter from 1 Apr 2023: $67K published
Quarter from 1 Jul 2023: $67K published
Quarter from 1 Oct 2023: $56K published
Quarter from 1 Jan 2024: $56K published
Quarter from 1 Apr 2024: $160K published
Quarter from 1 Jul 2024: $170K published
Quarter from 1 Oct 2024: $130K published
Quarter from 1 Jan 2025: $260K published
Quarter from 1 Apr 2025: $270K published
Quarter from 1 Jul 2025: $290K published
Quarter from 1 Oct 2025: $370K published
Quarter from 1 Jan 2026: $390K published
Quarter from 1 Apr 2026: $380K published
Quarter from 1 Jul 2026: $370K published
Quarter from 1 Oct 2026: $320K published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is capital expenditure, quarter at $52.9M (30 Sep 2026), 42% below its normal quarter of $90.5M; higher than 66% of its own history.
  • Insider net buying (open market): Insiders sold a net $12.7M in the last 12 months (the 12 months before: -$13.1M).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 48 published in the last 12 months, -7.7% on the 12 months before.
  • Revenue per quarter: Revenue $1.3B in the latest quarter, +11% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Last 90 days: 8 sales, $2.1M; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
18 Nov 2026Michael Jon BrownEVP Chief Legal Compliance OffSellplanned in advance (10b5-1)1,700$83.46$142KForm 4
28 Oct 2026Sadie SternEVP Chief People & Culture OffSellplanned in advance (10b5-1)2,565$78.62$202KForm 4
19 Oct 2026Michael Jon BrownEVP Chief Legal Compliance OffSellplanned in advance (10b5-1)1,700$85.48$145KForm 4
30 Sep 2026Sadie SternEVP Chief People & Culture OffSellplanned in advance (10b5-1)2,565$86.15$221KForm 4
16 Sep 2026Nicholas AugustinosDirectorSellplanned in advance (10b5-1)8,089$84.04$680KForm 4
16 Sep 2026Michael Jon BrownEVP Chief Legal Compliance OffSellplanned in advance (10b5-1)1,700$84.04$143KForm 4
14 Sep 2026Jereme M SylvainEVP, Chief Financal OfficerSellplanned in advance (10b5-1)3,638$83.27$303KForm 4
28 Aug 2026Sadie SternEVP Chief People & Culture OffSellplanned in advance (10b5-1)2,565$88.37$227KForm 4

1,038 institutions reported shares at the end of Q3 2026, 98% of the shares outstanding; 153 opened a position, 76 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
BlackRock, Inc.38.5M10.3%$3.3B+254K+0.7%
Vanguard Capital Management LLC24.7M6.62%$2.1B-505K-2.0%
Vanguard Portfolio Management LLC19.8M5.31%$1.7B+135K+0.7%
State Street Corp18.9M5.07%$1.6B+516K+2.8%
Invesco Ltd.16.0M4.28%$1.4B+681K+4.5%
Baillie Gifford & Co14.5M3.89%$1.3B-280K-1.9%
Geode Capital Management, LLC12.5M3.34%$1.1B+33K+0.3%
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC10.2M2.74%$880.3M-1.1M-9.4%
Arrowstreet Capital, Limited Partnership7.8M2.10%$675.2M+952K+14%
Wellington Management Group LLP5.2M1.39%$447.5M-3.3M-39%

Company events

All 53 company events

In 12 months: 5 director or officer changes. Results releases and routine reports are left out.

FiledWhat happenedSource
14 Sep 2026Director or officer change8-K
10 Sep 2026Director or officer change8-K
2 Mar 2026Director or officer change8-K
26 Feb 2026Director or officer change8-K
22 Dec 2025Director or officer change8-K
27 Oct 2025Director or officer change8-K
15 Sep 2025Director or officer change8-K
30 Jul 2025Director or officer change8-K

Reported lobbying spend: $320K in Q3 2026, $370K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
31 Jul 2026EndedContinental Strategy, LLCfor DexcomNot statedFiling
1 May 2026NewBGR Government Affairsfor DexcomProvide strategic counsel and advocate on issues related to Medicare coverage and regulatory policy.Medicare/MedicaidFiling
1 Jun 2025NewContinental Strategy, LLCfor Dexcomcontinuous glucose monitorsHealth issues, MEDFiling
1 Sep 2024NewFarragut Partners LLPfor Dexcom, Inc.General representation. Legislative and regulatory issues related to policies and payments for continuous glucose monitoringMedicare/MedicaidFiling
31 Mar 2020EndedArnold & Porter Kaye Scholer LLPfor Dexcom, Inc.Not statedFiling
1 Jul 2018EndedHCM Strategistsfor Dexcom, Inc.Not statedFiling
2 Feb 2018NewAlston & Bird LLPfor Dexcom, Inc.Issues related to coverage and reimbursement for continuous glucose monitor.Health issues, Medicare/MedicaidFiling
3 Jul 2017NewDexcom, Inc.its own lobbyistsCMS Coverage Issues, Technology development in health careManufacturing, Health issues, Medicare/Medicaid, Government issues, MED, Science/technologyFiling
Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

20 Oct 2022confirmed

Confirmed across sources Lobbying and Short interest and volume

DexCom (DXCM): lobbying on a new issue, while it had 13.0M shares sold short in the 30 Nov 2022 report, 3.6× the same report last year. Two unrelated kinds of activity within 77 days.

  • Short interest and volume: Short interest spike, became public on 27 Sep 2022
  • Short interest and volume: Short interest spike, became public on 13 Oct 2022
  • Lobbying: Lobbying on a new issue, became public on 20 Oct 2022
  • Short interest and volume: Short interest spike, became public on 26 Oct 2022
  • Short interest and volume: Short interest spike, became public on 10 Nov 2022
  • Short interest and volume: Short interest spike, became public on 26 Nov 2022
  • Short interest and volume: Short interest spike, became public on 10 Dec 2022
2021-11-15: 3.7M2021-11-30: 3.6M2021-12-15: 3.1M2022-01-14: 3.3M2022-01-31: 3.2M2022-02-15: 3.4M2022-02-28: 3.4M2022-03-15: 3.4M2022-03-31: 3.6M2022-04-14: 3.5M2022-04-29: 3.3M2022-05-13: 3.7M2022-05-31: 3.3M2022-06-15: 13.0M2022-06-30: 12.1M2022-07-15: 11.7M2022-07-29: 12.2M2022-08-15: 13.4M2022-08-31: 14.4M2022-09-15: 15.3M2022-09-30: 13.1M2022-10-14: 13.7M2022-10-31: 11.9M2022-11-15: 12.6M2022-11-30: 13.0M
The 30 Nov 2022 report against the 24 reports before it. this reportearliernormal: 3.7M
See the evidence (7 changes)

Short interest and volume: Short interest spike became public on 27 Sep 2022

DexCom had 15.3M shares sold short in the 15 Sep 2022 report, 4.2× the same report last year.

This period
15.3M (the 15 Sep 2022 report)
Normal report (median of 24 earlier)
3.6M
Typical spread (median absolute deviation)
193K
How far from its usual level
+32.9
Same report last year
3.6M
History used
1,721 days
2021-08-31: 3.8M2021-09-15: 3.6M2021-09-30: 3.4M2021-10-15: 3.5M2021-10-29: 3.6M2021-11-15: 3.7M2021-11-30: 3.6M2021-12-15: 3.1M2022-01-14: 3.3M2022-01-31: 3.2M2022-02-15: 3.4M2022-02-28: 3.4M2022-03-15: 3.4M2022-03-31: 3.6M2022-04-14: 3.5M2022-04-29: 3.3M2022-05-13: 3.7M2022-05-31: 3.3M2022-06-15: 13.0M2022-06-30: 12.1M2022-07-15: 11.7M2022-07-29: 12.2M2022-08-15: 13.4M2022-08-31: 14.4M2022-09-15: 15.3M
the 15 Sep 2022 report24 earlier reportsnormal: 3.6M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 13 Oct 2022

DexCom had 13.1M shares sold short in the 30 Sep 2022 report, 3.8× the same report last year.

This period
13.1M (the 30 Sep 2022 report)
Normal report (median of 24 earlier)
3.6M
Typical spread (median absolute deviation)
193K
How far from its usual level
+26.8
Same report last year
3.4M
History used
1,736 days
2021-09-15: 3.6M2021-09-30: 3.4M2021-10-15: 3.5M2021-10-29: 3.6M2021-11-15: 3.7M2021-11-30: 3.6M2021-12-15: 3.1M2022-01-14: 3.3M2022-01-31: 3.2M2022-02-15: 3.4M2022-02-28: 3.4M2022-03-15: 3.4M2022-03-31: 3.6M2022-04-14: 3.5M2022-04-29: 3.3M2022-05-13: 3.7M2022-05-31: 3.3M2022-06-15: 13.0M2022-06-30: 12.1M2022-07-15: 11.7M2022-07-29: 12.2M2022-08-15: 13.4M2022-08-31: 14.4M2022-09-15: 15.3M2022-09-30: 13.1M
the 30 Sep 2022 report24 earlier reportsnormal: 3.6M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Lobbying: Lobbying on a new issue became public on 20 Oct 2022

DexCom lobbying on a new issue.

New
['ECN']
Rule
only points whose every posting (and value revision) is at or before as_of
Field
issue_codes
Metric
lobbying.filings_count
Point id
12627937

Short interest and volume: Short interest spike became public on 26 Oct 2022

DexCom had 13.7M shares sold short in the 14 Oct 2022 report, 3.9× the same report last year.

This period
13.7M (the 14 Oct 2022 report)
Normal report (median of 24 earlier)
3.6M
Typical spread (median absolute deviation)
228K
How far from its usual level
+28.5
Same report last year
3.5M
History used
1,750 days
2021-09-30: 3.4M2021-10-15: 3.5M2021-10-29: 3.6M2021-11-15: 3.7M2021-11-30: 3.6M2021-12-15: 3.1M2022-01-14: 3.3M2022-01-31: 3.2M2022-02-15: 3.4M2022-02-28: 3.4M2022-03-15: 3.4M2022-03-31: 3.6M2022-04-14: 3.5M2022-04-29: 3.3M2022-05-13: 3.7M2022-05-31: 3.3M2022-06-15: 13.0M2022-06-30: 12.1M2022-07-15: 11.7M2022-07-29: 12.2M2022-08-15: 13.4M2022-08-31: 14.4M2022-09-15: 15.3M2022-09-30: 13.1M2022-10-14: 13.7M
the 14 Oct 2022 report24 earlier reportsnormal: 3.6M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 10 Nov 2022

DexCom had 11.9M shares sold short in the 31 Oct 2022 report, 3.3× the same report last year.

This period
11.9M (the 31 Oct 2022 report)
Normal report (median of 24 earlier)
3.6M
Typical spread (median absolute deviation)
294K
How far from its usual level
+19.0
Same report last year
3.6M
History used
1,767 days
2021-10-15: 3.5M2021-10-29: 3.6M2021-11-15: 3.7M2021-11-30: 3.6M2021-12-15: 3.1M2022-01-14: 3.3M2022-01-31: 3.2M2022-02-15: 3.4M2022-02-28: 3.4M2022-03-15: 3.4M2022-03-31: 3.6M2022-04-14: 3.5M2022-04-29: 3.3M2022-05-13: 3.7M2022-05-31: 3.3M2022-06-15: 13.0M2022-06-30: 12.1M2022-07-15: 11.7M2022-07-29: 12.2M2022-08-15: 13.4M2022-08-31: 14.4M2022-09-15: 15.3M2022-09-30: 13.1M2022-10-14: 13.7M2022-10-31: 11.9M
the 31 Oct 2022 report24 earlier reportsnormal: 3.6M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 26 Nov 2022

DexCom had 12.6M shares sold short in the 15 Nov 2022 report, 3.4× the same report last year.

This period
12.6M (the 15 Nov 2022 report)
Normal report (median of 24 earlier)
3.6M
Typical spread (median absolute deviation)
396K
How far from its usual level
+15.3
Same report last year
3.7M
History used
1,782 days
2021-10-29: 3.6M2021-11-15: 3.7M2021-11-30: 3.6M2021-12-15: 3.1M2022-01-14: 3.3M2022-01-31: 3.2M2022-02-15: 3.4M2022-02-28: 3.4M2022-03-15: 3.4M2022-03-31: 3.6M2022-04-14: 3.5M2022-04-29: 3.3M2022-05-13: 3.7M2022-05-31: 3.3M2022-06-15: 13.0M2022-06-30: 12.1M2022-07-15: 11.7M2022-07-29: 12.2M2022-08-15: 13.4M2022-08-31: 14.4M2022-09-15: 15.3M2022-09-30: 13.1M2022-10-14: 13.7M2022-10-31: 11.9M2022-11-15: 12.6M
the 15 Nov 2022 report24 earlier reportsnormal: 3.6M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 10 Dec 2022

DexCom had 13.0M shares sold short in the 30 Nov 2022 report, 3.6× the same report last year.

This period
13.0M (the 30 Nov 2022 report)
Normal report (median of 24 earlier)
3.7M
Typical spread (median absolute deviation)
509K
How far from its usual level
+12.3
Same report last year
3.6M
History used
1,797 days
2021-11-15: 3.7M2021-11-30: 3.6M2021-12-15: 3.1M2022-01-14: 3.3M2022-01-31: 3.2M2022-02-15: 3.4M2022-02-28: 3.4M2022-03-15: 3.4M2022-03-31: 3.6M2022-04-14: 3.5M2022-04-29: 3.3M2022-05-13: 3.7M2022-05-31: 3.3M2022-06-15: 13.0M2022-06-30: 12.1M2022-07-15: 11.7M2022-07-29: 12.2M2022-08-15: 13.4M2022-08-31: 14.4M2022-09-15: 15.3M2022-09-30: 13.1M2022-10-14: 13.7M2022-10-31: 11.9M2022-11-15: 12.6M2022-11-30: 13.0M
the 30 Nov 2022 report24 earlier reportsnormal: 3.7M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

1 Jan 2019confirmed

Confirmed across sources Institutional holdings and Filings + Financials

DexCom (DXCM): saw 84 13F filers open a new position in the quarter ended 30 Sep 2018, 3.2× the same quarter last year, while it reported revenue of $266.7M for the quarter ended 30 Sep 2018, 1.4× the same quarter last year. Two unrelated kinds of activity on the same day.

  • Institutional holdings: Many funds opening a new position, became public on 14 Nov 2018
  • Financials: Quarterly revenue change, became public on 1 Jan 2019
2016-09-30: 392016-12-31: 662017-03-31: 492017-06-30: 302017-09-30: 262017-12-31: 442018-03-31: 432018-06-30: 462018-09-30: 84
The quarter ended 30 Sep 2018 against the 8 quarters before it. this quarterearliernormal: 43.5
See the evidence (2 changes)

Institutional holdings: Many funds opening a new position became public on 14 Nov 2018

DexCom saw 84 13F filers open a new position in the quarter ended 30 Sep 2018, 3.2× the same quarter last year.

This period
84 (the quarter ended 30 Sep 2018)
Normal quarter (median of 8 earlier)
43.5
Typical spread (median absolute deviation)
5
How far from its usual level
+5.5
Same quarter last year
26
History used
1,826 days
2016-09-30: 392016-12-31: 662017-03-31: 492017-06-30: 302017-09-30: 262017-12-31: 442018-03-31: 432018-06-30: 462018-09-30: 84
the quarter ended 30 Sep 20188 earlier quartersnormal: 43.5

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Financials: Quarterly revenue change became public on 1 Jan 2019

DexCom reported revenue of $266.7M for the quarter ended 30 Sep 2018, 1.4× the same quarter last year.

This period
$266.7M (the quarter ended 30 Sep 2018)
Normal quarter (median of 8 earlier)
$177.8M
Typical spread (median absolute deviation)
$18.2M
How far from its usual level
+3.3
Same quarter last year
$184.6M
History used
3,105 days
2016-09-30: $148.6M2016-12-31: $171.2M2017-03-31: $142.3M2017-06-30: $170.6M2017-09-30: $184.6M2017-12-31: $221.0M2018-03-31: $184.4M2018-06-30: $242.5M2018-09-30: $266.7M
the quarter ended 30 Sep 20188 earlier quartersnormal: $177.8M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 19 Oct 2026Lobbying record

    DEXCOM: lobbying engagement terminated (CONTINENTAL STRATEGY, LLC) (dated 31 Jul 2026)

  2. 14 Sep 2026Filings record

    Director or officer change

  3. 10 Sep 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  4. 10 Sep 2026Filings record

    Director or officer change

  5. 15 Jun 2026Lobbying record

    DEXCOM: new lobbying registration (BGR GOVERNMENT AFFAIRS) (dated 1 May 2026)

  6. 2 Mar 2026Filings record

    Director or officer change

  7. 26 Feb 2026Filings record

    Director or officer change

  8. 22 Dec 2025Filings record

    Director or officer change

  9. 11 Nov 2025Insiders record

    Leach Jacob Steven (President & COO) bought 18,200 shares of DXCM ($1.0M) (dated 10 Nov 2025)

  10. 27 Oct 2025Filings record

    Director or officer change

  11. 15 Sep 2025Filings record

    Director or officer change

  12. 30 Jul 2025Filings record

    Director or officer change

  13. 21 Jul 2025Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['MED']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    4822872
  14. 11 Jun 2025Lobbying record

    DEXCOM: new lobbying registration (CONTINENTAL STRATEGY, LLC) (dated 1 Jun 2025)

  15. 13 May 2025Filings record

    Director or officer change

  16. 9 May 2025Filings record

    Director or officer change

  17. 2 May 2025Filings record

    Director or officer change

  18. 25 Mar 2025Filings record

    Changed its auditor

  19. 10 Mar 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  20. 10 Mar 2025Filings record

    Director or officer change

  21. 25 Feb 2025Financials change

    spent $124.6M on capital projects in the quarter ended 31 Dec 2024, 2.4× the same quarter last year.

    Same quarter last year: $52.5M; its normal quarter is $61.2M.

    See the evidence
    This period
    $124.6M (the quarter ended 31 Dec 2024)
    Normal quarter (median of 8 earlier)
    $61.2M
    Typical spread (median absolute deviation)
    $6.8M
    How far from its usual level
    +6.3
    Same quarter last year
    $52.5M
    History used
    5,206 days
    2022-12-31: $63.5M2023-03-31: $74.7M2023-06-30: $59.0M2023-09-30: $50.4M2023-12-31: $52.5M2024-03-31: $56.9M2024-06-30: $66.1M2024-09-30: $111.2M2024-12-31: $124.6M
    the quarter ended 31 Dec 20248 earlier quartersnormal: $61.2M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  22. 21 Jan 2025Lobbying change

    reported $260K of lobbying spend for the quarter ended 31 Dec 2024, 4.6× the same quarter last year.

    Same quarter last year: $56K; its normal quarter is $67K.

    See the evidence
    This period
    $260K (the quarter ended 31 Dec 2024)
    Normal quarter (median of 8 earlier)
    $67K
    Typical spread (median absolute deviation)
    $11K
    How far from its usual level
    +9.6
    Same quarter last year
    $56K
    History used
    3,928 days
    2022-12-31: $62K2023-03-31: $67K2023-06-30: $67K2023-09-30: $56K2023-12-31: $56K2024-03-31: $160K2024-06-30: $170K2024-09-30: $130K2024-12-31: $260K
    the quarter ended 31 Dec 20248 earlier quartersnormal: $67K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.

    Check it at the source: Senate/House lobbying disclosures (LDA).

  23. 29 Oct 2024Financials change

    spent $111.2M on capital projects in the quarter ended 30 Sep 2024, 2.2× the same quarter last year.

    Same quarter last year: $50.4M; its normal quarter is $61.2M.

    See the evidence
    This period
    $111.2M (the quarter ended 30 Sep 2024)
    Normal quarter (median of 8 earlier)
    $61.2M
    Typical spread (median absolute deviation)
    $6.8M
    How far from its usual level
    +5.0
    Same quarter last year
    $50.4M
    History used
    5,114 days
    2022-09-30: $108.2M2022-12-31: $63.5M2023-03-31: $74.7M2023-06-30: $59.0M2023-09-30: $50.4M2023-12-31: $52.5M2024-03-31: $56.9M2024-06-30: $66.1M2024-09-30: $111.2M
    the quarter ended 30 Sep 20248 earlier quartersnormal: $61.2M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  24. 27 Sep 2024Lobbying record

    DEXCOM, INC.: new lobbying registration (FARRAGUT PARTNERS LLP) (dated 1 Sep 2024)

  25. 22 Jul 2024Lobbying change

    reported $170K of lobbying spend for the quarter ended 30 Jun 2024, 2.5× the same quarter last year.

    Same quarter last year: $67K; its normal quarter is $60K.

    See the evidence
    This period
    $170K (the quarter ended 30 Jun 2024)
    Normal quarter (median of 8 earlier)
    $60K
    Typical spread (median absolute deviation)
    $3K
    How far from its usual level
    +5.5
    Same quarter last year
    $67K
    History used
    3,744 days
    2022-06-30: $57K2022-09-30: $56K2022-12-31: $62K2023-03-31: $67K2023-06-30: $67K2023-09-30: $56K2023-12-31: $56K2024-03-31: $160K2024-06-30: $170K
    the quarter ended 30 Jun 20248 earlier quartersnormal: $60K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.

    Check it at the source: Senate/House lobbying disclosures (LDA).

  26. 22 Apr 2024Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['TRD']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    6540668
  27. 15 Feb 2024Filings record

    A major agreement ended

  28. 13 Feb 2024Financials change

    reported revenue of $1.0B for the quarter ended 31 Dec 2023, 1.3× the same quarter last year.

    Same quarter last year: $815.2M; its normal quarter is $755.5M.

    See the evidence
    This period
    $1.0B (the quarter ended 31 Dec 2023)
    Normal quarter (median of 8 earlier)
    $755.5M
    Typical spread (median absolute deviation)
    $59.5M
    How far from its usual level
    +3.2
    Same quarter last year
    $815.2M
    History used
    5,023 days
    2021-12-31: $698.2M2022-03-31: $628.8M2022-06-30: $696.2M2022-09-30: $769.6M2022-12-31: $815.2M2023-03-31: $741.5M2023-06-30: $871.3M2023-09-30: $975.0M2023-12-31: $1.0B
    the quarter ended 31 Dec 20238 earlier quartersnormal: $755.5M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  29. 28 Nov 2023Short interest and volume change

    had 17.7M shares sold short in the 15 Nov 2023 report, 1.4× the same report last year.

    Same report last year: 12.6M; its normal report is 12.8M.

    See the evidence
    This period
    17.7M (the 15 Nov 2023 report)
    Normal report (median of 24 earlier)
    12.8M
    Typical spread (median absolute deviation)
    902K
    How far from its usual level
    +3.7
    Same report last year
    12.6M
    History used
    2,147 days
    2022-11-15: 12.6M2022-11-30: 13.0M2022-12-15: 12.5M2022-12-30: 11.6M2023-01-13: 11.8M2023-01-31: 11.1M2023-02-15: 13.2M2023-02-28: 12.9M2023-03-15: 12.6M2023-03-31: 12.4M2023-04-14: 12.1M2023-04-28: 12.7M2023-05-15: 14.5M2023-05-31: 14.3M2023-06-15: 12.7M2023-06-30: 12.4M2023-07-14: 12.4M2023-07-31: 15.0M2023-08-15: 16.8M2023-08-31: 16.9M2023-09-15: 16.0M2023-09-29: 15.8M2023-10-13: 16.1M2023-10-31: 21.1M2023-11-15: 17.7M
    the 15 Nov 2023 report24 earlier reportsnormal: 12.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  30. 10 Nov 2023Short interest and volume change

    had 21.1M shares sold short in the 31 Oct 2023 report, 1.8× the same report last year.

    Same report last year: 11.9M; its normal report is 12.7M.

    See the evidence
    This period
    21.1M (the 31 Oct 2023 report)
    Normal report (median of 24 earlier)
    12.7M
    Typical spread (median absolute deviation)
    726K
    How far from its usual level
    +6.6
    Same report last year
    11.9M
    History used
    2,132 days
    2022-10-31: 11.9M2022-11-15: 12.6M2022-11-30: 13.0M2022-12-15: 12.5M2022-12-30: 11.6M2023-01-13: 11.8M2023-01-31: 11.1M2023-02-15: 13.2M2023-02-28: 12.9M2023-03-15: 12.6M2023-03-31: 12.4M2023-04-14: 12.1M2023-04-28: 12.7M2023-05-15: 14.5M2023-05-31: 14.3M2023-06-15: 12.7M2023-06-30: 12.4M2023-07-14: 12.4M2023-07-31: 15.0M2023-08-15: 16.8M2023-08-31: 16.9M2023-09-15: 16.0M2023-09-29: 15.8M2023-10-13: 16.1M2023-10-31: 21.1M
    the 31 Oct 2023 report24 earlier reportsnormal: 12.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  31. 28 Aug 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  32. 28 Aug 2023Filings record

    Director or officer change

  33. 19 May 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  34. 19 May 2023Filings record

    Director or officer change

  35. 14 Feb 2023Institutional holdings change

    saw 123 13F filers open a new position in the quarter ended 31 Dec 2022, 2.4% below the same quarter last year.

    Same quarter last year: 126; its normal quarter is 69.5.

    See the evidence
    This period
    123 (the quarter ended 31 Dec 2022)
    Normal quarter (median of 8 earlier)
    69.5
    Typical spread (median absolute deviation)
    4
    How far from its usual level
    +7.7
    Same quarter last year
    126
    History used
    3,379 days
    2020-12-31: 712021-03-31: 682021-06-30: 672021-09-30: 1022021-12-31: 1262022-03-31: 602022-06-30: 712022-09-30: 642022-12-31: 123
    the quarter ended 31 Dec 20228 earlier quartersnormal: 69.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  36. 10 Dec 2022Short interest and volume change

    had 13.0M shares sold short in the 30 Nov 2022 report, 3.6× the same report last year.

    Same report last year: 3.6M; its normal report is 3.7M.

    See the evidence
    This period
    13.0M (the 30 Nov 2022 report)
    Normal report (median of 24 earlier)
    3.7M
    Typical spread (median absolute deviation)
    509K
    How far from its usual level
    +12.3
    Same report last year
    3.6M
    History used
    1,797 days
    2021-11-15: 3.7M2021-11-30: 3.6M2021-12-15: 3.1M2022-01-14: 3.3M2022-01-31: 3.2M2022-02-15: 3.4M2022-02-28: 3.4M2022-03-15: 3.4M2022-03-31: 3.6M2022-04-14: 3.5M2022-04-29: 3.3M2022-05-13: 3.7M2022-05-31: 3.3M2022-06-15: 13.0M2022-06-30: 12.1M2022-07-15: 11.7M2022-07-29: 12.2M2022-08-15: 13.4M2022-08-31: 14.4M2022-09-15: 15.3M2022-09-30: 13.1M2022-10-14: 13.7M2022-10-31: 11.9M2022-11-15: 12.6M2022-11-30: 13.0M
    the 30 Nov 2022 report24 earlier reportsnormal: 3.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  37. 26 Nov 2022Short interest and volume change

    had 12.6M shares sold short in the 15 Nov 2022 report, 3.4× the same report last year.

    Same report last year: 3.7M; its normal report is 3.6M.

    See the evidence
    This period
    12.6M (the 15 Nov 2022 report)
    Normal report (median of 24 earlier)
    3.6M
    Typical spread (median absolute deviation)
    396K
    How far from its usual level
    +15.3
    Same report last year
    3.7M
    History used
    1,782 days
    2021-10-29: 3.6M2021-11-15: 3.7M2021-11-30: 3.6M2021-12-15: 3.1M2022-01-14: 3.3M2022-01-31: 3.2M2022-02-15: 3.4M2022-02-28: 3.4M2022-03-15: 3.4M2022-03-31: 3.6M2022-04-14: 3.5M2022-04-29: 3.3M2022-05-13: 3.7M2022-05-31: 3.3M2022-06-15: 13.0M2022-06-30: 12.1M2022-07-15: 11.7M2022-07-29: 12.2M2022-08-15: 13.4M2022-08-31: 14.4M2022-09-15: 15.3M2022-09-30: 13.1M2022-10-14: 13.7M2022-10-31: 11.9M2022-11-15: 12.6M
    the 15 Nov 2022 report24 earlier reportsnormal: 3.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  38. 10 Nov 2022Short interest and volume change

    had 11.9M shares sold short in the 31 Oct 2022 report, 3.3× the same report last year.

    Same report last year: 3.6M; its normal report is 3.6M.

    See the evidence
    This period
    11.9M (the 31 Oct 2022 report)
    Normal report (median of 24 earlier)
    3.6M
    Typical spread (median absolute deviation)
    294K
    How far from its usual level
    +19.0
    Same report last year
    3.6M
    History used
    1,767 days
    2021-10-15: 3.5M2021-10-29: 3.6M2021-11-15: 3.7M2021-11-30: 3.6M2021-12-15: 3.1M2022-01-14: 3.3M2022-01-31: 3.2M2022-02-15: 3.4M2022-02-28: 3.4M2022-03-15: 3.4M2022-03-31: 3.6M2022-04-14: 3.5M2022-04-29: 3.3M2022-05-13: 3.7M2022-05-31: 3.3M2022-06-15: 13.0M2022-06-30: 12.1M2022-07-15: 11.7M2022-07-29: 12.2M2022-08-15: 13.4M2022-08-31: 14.4M2022-09-15: 15.3M2022-09-30: 13.1M2022-10-14: 13.7M2022-10-31: 11.9M
    the 31 Oct 2022 report24 earlier reportsnormal: 3.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  39. 26 Oct 2022Short interest and volume change

    had 13.7M shares sold short in the 14 Oct 2022 report, 3.9× the same report last year.

    Same report last year: 3.5M; its normal report is 3.6M.

    See the evidence
    This period
    13.7M (the 14 Oct 2022 report)
    Normal report (median of 24 earlier)
    3.6M
    Typical spread (median absolute deviation)
    228K
    How far from its usual level
    +28.5
    Same report last year
    3.5M
    History used
    1,750 days
    2021-09-30: 3.4M2021-10-15: 3.5M2021-10-29: 3.6M2021-11-15: 3.7M2021-11-30: 3.6M2021-12-15: 3.1M2022-01-14: 3.3M2022-01-31: 3.2M2022-02-15: 3.4M2022-02-28: 3.4M2022-03-15: 3.4M2022-03-31: 3.6M2022-04-14: 3.5M2022-04-29: 3.3M2022-05-13: 3.7M2022-05-31: 3.3M2022-06-15: 13.0M2022-06-30: 12.1M2022-07-15: 11.7M2022-07-29: 12.2M2022-08-15: 13.4M2022-08-31: 14.4M2022-09-15: 15.3M2022-09-30: 13.1M2022-10-14: 13.7M
    the 14 Oct 2022 report24 earlier reportsnormal: 3.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  40. 20 Oct 2022several at once

    lobbying on a new issue, while it had 13.0M shares sold short in the 30 Nov 2022 report, 3.6× the same report last year. Two unrelated kinds of activity within 77 days.

    See the evidence (7 changes)

    Short interest and volume: Short interest spike became public on 27 Sep 2022

    DexCom had 15.3M shares sold short in the 15 Sep 2022 report, 4.2× the same report last year.

    This period
    15.3M (the 15 Sep 2022 report)
    Normal report (median of 24 earlier)
    3.6M
    Typical spread (median absolute deviation)
    193K
    How far from its usual level
    +32.9
    Same report last year
    3.6M
    History used
    1,721 days
    2021-08-31: 3.8M2021-09-15: 3.6M2021-09-30: 3.4M2021-10-15: 3.5M2021-10-29: 3.6M2021-11-15: 3.7M2021-11-30: 3.6M2021-12-15: 3.1M2022-01-14: 3.3M2022-01-31: 3.2M2022-02-15: 3.4M2022-02-28: 3.4M2022-03-15: 3.4M2022-03-31: 3.6M2022-04-14: 3.5M2022-04-29: 3.3M2022-05-13: 3.7M2022-05-31: 3.3M2022-06-15: 13.0M2022-06-30: 12.1M2022-07-15: 11.7M2022-07-29: 12.2M2022-08-15: 13.4M2022-08-31: 14.4M2022-09-15: 15.3M
    the 15 Sep 2022 report24 earlier reportsnormal: 3.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 13 Oct 2022

    DexCom had 13.1M shares sold short in the 30 Sep 2022 report, 3.8× the same report last year.

    This period
    13.1M (the 30 Sep 2022 report)
    Normal report (median of 24 earlier)
    3.6M
    Typical spread (median absolute deviation)
    193K
    How far from its usual level
    +26.8
    Same report last year
    3.4M
    History used
    1,736 days
    2021-09-15: 3.6M2021-09-30: 3.4M2021-10-15: 3.5M2021-10-29: 3.6M2021-11-15: 3.7M2021-11-30: 3.6M2021-12-15: 3.1M2022-01-14: 3.3M2022-01-31: 3.2M2022-02-15: 3.4M2022-02-28: 3.4M2022-03-15: 3.4M2022-03-31: 3.6M2022-04-14: 3.5M2022-04-29: 3.3M2022-05-13: 3.7M2022-05-31: 3.3M2022-06-15: 13.0M2022-06-30: 12.1M2022-07-15: 11.7M2022-07-29: 12.2M2022-08-15: 13.4M2022-08-31: 14.4M2022-09-15: 15.3M2022-09-30: 13.1M
    the 30 Sep 2022 report24 earlier reportsnormal: 3.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Lobbying: Lobbying on a new issue became public on 20 Oct 2022

    DexCom lobbying on a new issue.

    New
    ['ECN']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    12627937

    Short interest and volume: Short interest spike became public on 26 Oct 2022

    DexCom had 13.7M shares sold short in the 14 Oct 2022 report, 3.9× the same report last year.

    This period
    13.7M (the 14 Oct 2022 report)
    Normal report (median of 24 earlier)
    3.6M
    Typical spread (median absolute deviation)
    228K
    How far from its usual level
    +28.5
    Same report last year
    3.5M
    History used
    1,750 days
    2021-09-30: 3.4M2021-10-15: 3.5M2021-10-29: 3.6M2021-11-15: 3.7M2021-11-30: 3.6M2021-12-15: 3.1M2022-01-14: 3.3M2022-01-31: 3.2M2022-02-15: 3.4M2022-02-28: 3.4M2022-03-15: 3.4M2022-03-31: 3.6M2022-04-14: 3.5M2022-04-29: 3.3M2022-05-13: 3.7M2022-05-31: 3.3M2022-06-15: 13.0M2022-06-30: 12.1M2022-07-15: 11.7M2022-07-29: 12.2M2022-08-15: 13.4M2022-08-31: 14.4M2022-09-15: 15.3M2022-09-30: 13.1M2022-10-14: 13.7M
    the 14 Oct 2022 report24 earlier reportsnormal: 3.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 10 Nov 2022

    DexCom had 11.9M shares sold short in the 31 Oct 2022 report, 3.3× the same report last year.

    This period
    11.9M (the 31 Oct 2022 report)
    Normal report (median of 24 earlier)
    3.6M
    Typical spread (median absolute deviation)
    294K
    How far from its usual level
    +19.0
    Same report last year
    3.6M
    History used
    1,767 days
    2021-10-15: 3.5M2021-10-29: 3.6M2021-11-15: 3.7M2021-11-30: 3.6M2021-12-15: 3.1M2022-01-14: 3.3M2022-01-31: 3.2M2022-02-15: 3.4M2022-02-28: 3.4M2022-03-15: 3.4M2022-03-31: 3.6M2022-04-14: 3.5M2022-04-29: 3.3M2022-05-13: 3.7M2022-05-31: 3.3M2022-06-15: 13.0M2022-06-30: 12.1M2022-07-15: 11.7M2022-07-29: 12.2M2022-08-15: 13.4M2022-08-31: 14.4M2022-09-15: 15.3M2022-09-30: 13.1M2022-10-14: 13.7M2022-10-31: 11.9M
    the 31 Oct 2022 report24 earlier reportsnormal: 3.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 26 Nov 2022

    DexCom had 12.6M shares sold short in the 15 Nov 2022 report, 3.4× the same report last year.

    This period
    12.6M (the 15 Nov 2022 report)
    Normal report (median of 24 earlier)
    3.6M
    Typical spread (median absolute deviation)
    396K
    How far from its usual level
    +15.3
    Same report last year
    3.7M
    History used
    1,782 days
    2021-10-29: 3.6M2021-11-15: 3.7M2021-11-30: 3.6M2021-12-15: 3.1M2022-01-14: 3.3M2022-01-31: 3.2M2022-02-15: 3.4M2022-02-28: 3.4M2022-03-15: 3.4M2022-03-31: 3.6M2022-04-14: 3.5M2022-04-29: 3.3M2022-05-13: 3.7M2022-05-31: 3.3M2022-06-15: 13.0M2022-06-30: 12.1M2022-07-15: 11.7M2022-07-29: 12.2M2022-08-15: 13.4M2022-08-31: 14.4M2022-09-15: 15.3M2022-09-30: 13.1M2022-10-14: 13.7M2022-10-31: 11.9M2022-11-15: 12.6M
    the 15 Nov 2022 report24 earlier reportsnormal: 3.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 10 Dec 2022

    DexCom had 13.0M shares sold short in the 30 Nov 2022 report, 3.6× the same report last year.

    This period
    13.0M (the 30 Nov 2022 report)
    Normal report (median of 24 earlier)
    3.7M
    Typical spread (median absolute deviation)
    509K
    How far from its usual level
    +12.3
    Same report last year
    3.6M
    History used
    1,797 days
    2021-11-15: 3.7M2021-11-30: 3.6M2021-12-15: 3.1M2022-01-14: 3.3M2022-01-31: 3.2M2022-02-15: 3.4M2022-02-28: 3.4M2022-03-15: 3.4M2022-03-31: 3.6M2022-04-14: 3.5M2022-04-29: 3.3M2022-05-13: 3.7M2022-05-31: 3.3M2022-06-15: 13.0M2022-06-30: 12.1M2022-07-15: 11.7M2022-07-29: 12.2M2022-08-15: 13.4M2022-08-31: 14.4M2022-09-15: 15.3M2022-09-30: 13.1M2022-10-14: 13.7M2022-10-31: 11.9M2022-11-15: 12.6M2022-11-30: 13.0M
    the 30 Nov 2022 report24 earlier reportsnormal: 3.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Showing the newest 40 of 105 entries; narrow the window or the kind of data to see older ones.

Not listed: 811 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001093557
Ticker
DXCM
Domain
dexcom.com
Employer name
Dexcom, Inc. (1 unverified)
Hq location
CA|SAN DIEGO|92121 (1 unverified)
Lobbying client
dexcom
Name
DexCom, Inc., DEXCOM INTERNATIONAL LIMITED, DEXCOM (MALAYSIA) SDN. BHD
Uei
RV5DCZ7N11J3
Wikidata
Q15109865
Wikipedia
Dexcom
  • DOL H-1B labor condition applications and PERM certifications1117 data points4 Nov 2019 to 21 Sep 2026
  • Federal lobbying disclosures (LDA)11 records, 166 data points31 Dec 2006 to 30 Sep 2026
  • SEC Form 13F institutional holdings1 record, 481 data points30 Jun 2013 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)183 records12 Jan 2016 to 29 Oct 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)1293 data points31 Dec 2008 to 22 Oct 2026
  • SEC Form 4 insider transactions672 records, 1760 data points11 Jan 2016 to 18 Nov 2026
  • FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
  • USASpending.gov federal awards165 data points23 Apr 2008 to 18 Oct 2021
  • Wikipedia pageviews2882 data points1 Jan 2019 to 21 Nov 2026